Citation Impact
Citing Papers
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
2000
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.
1995 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
1995 StandoutNobel
Phosphatidylinositol metabolism accompanies early activation events in tumor target cell-stimulated human natural killer cells
1988
The relationship between social support and physiological processes: A review with emphasis on underlying mechanisms and implications for health.
1996 Standout
Nucleotide signalling during inflammation
2014 StandoutNature
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
2004 Standout
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Extracellular adenosine triphosphate and adenosine in cancer
2010
The history, properties, and biological effects of cachectin
1988 StandoutNobel
Studies on the mechanism of cortisol inhibition of human natural killer cell activity: Effects of calcium entry blockers and calmodulin antagonists
1987
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
1992 StandoutNature
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Pregnancy Maintenance and Parturition: The Role of Prostaglandin in Manipulating the Immune and Inflammatory Response
1994
Antitumour actions of interferons: implications for cancer therapy
2016
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
1997 StandoutNature
Engineering interferons and interleukins for cancer immunotherapy
2022
Functions of natural killer cells
2008 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Biology of Natural Killer Cells
1989 Standout
Human Growth Hormone and Human Aging
1993
INTERFERON-?? TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1
1998
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Rho GTPases and signaling networks
1997 Standout
Expression of cyclo-oxygenase in human endometrium during the implantation period
1999
Resveratrol Inhibits Cyclooxygenase-2 Transcription and Activity in Phorbol Ester-treated Human Mammary Epithelial Cells
1998 Standout
Immunoregulatory properties of growth hormone and prolactin
1996
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
1991 Standout
Management of Metastatic Melanoma 2005
2006
The metabolic effects of tumor necrosis factor and other cytokines
1991
Clinical Pharmacokinetics of Interferons
1990
Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor
2015
Interferons modulate the expression of hormone receptors on the surface of murine melanoma cells.
1989
Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats
1998
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
1989
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Modulation of natural killer-mediated lysis by red blood cells
1988
Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.
1987
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Regulation of human natural cytotoxicity by IgG
1988
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Epstein–Barr Virus Infection
2000 Standout
Mechanisms of implantation: strategies for successful pregnancy
2012 Standout
Type 1 Interferons and Antiviral CD8 T-Cell Responses
2012
Myocarditis
2009 Standout
Interferon γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis
2001
Local and Systemic Effects of Intradermal Recombinant Interferon-γ in Patients with Lepromatous Leprosy
1986 StandoutNobel
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.
1989 Standout
Interaction of recombinant interferons with recombinant interleukin‐2: Differential effects on natural killer cell activity and interleukin‐2‐activated killer cells
1986
Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes
1987
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
2011
Prevention of viral myocarditis with recombinant human leukocyte interferon α A/D in a murine model
1987
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Relationship between circulating interferon and anti‐interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus
1985
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 Standout
Natural Killer Cells in Connective Tissue Disorders
1985
Role of natural killer cells in infection with the mouse pneumonitis agent (murine Chlamydia trachomatis)
1987
The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis
1988 StandoutScience
Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.
1986
Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes.
1996
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Graft-versus-leukemia reactions after bone marrow transplantation
1990 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.
1993 Standout
Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study
1985
Interferon in the Treatment of Cutaneous T-cell Lymphoma
1995
Phase I trial of recombinant interferon gamma in cancer patients.
1986
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.
1985
The control of specificity of cytotoxic T lymphocytes by the major histocompatibility complex (AG-B) in rats and identification of a new alloantigen system showing no AG-B restriction.
1977 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Ceramide inhibition of phospholipase D and its relationship to RhoA and ARF1 translocation in GTPγS-stimulated polymorphonuclear leukocytes
2003 StandoutNobel
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
The pathogenesis of cancer metastasis
1980 StandoutNature
Immune Interventions in Disease
1987
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
1993 StandoutScience
Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma
2003 StandoutNobel
Specificity of cell-mediated transplantation reactions in rats detected by the macrophage adherence inhibition test
1977
Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes
2010
The functional loss of human natural killer cell activity induced by K562 is reversible via an interleukin-2-dependent mechanism
1986
The Biology of Cancer Invasion and Metastasis
1978
Biological therapy of cancer
1986
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
1999
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
2001
Works of A E Maluish being referenced
The determination of an immunologically active dose of interferon-gamma in patients with melanoma.
1988
Lymphocyte subset distribution and natural killer activity in growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone
1988
A phase I trial of recombinant gamma interferon in patients with cancer
1985
Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity.
1983
Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2.
1985
Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
1990
A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer.
1984
Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
1983
Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I.
1986
Detection of Anti-tumour Cell Mediated Immunity and Serum Blocking Factors in Cancer Patients by the Leucocyte Adherence Inhibition Test
1974
A Multiple-Dose Phase I Trial of Recombinant Leukocyte A Interferon in Cancer Patients
1982